Perspective | Published:

Testing the 10 most wanted: a preclinical algorithm to screen candidate opioid use disorder medications

Neuropsychopharmacologyvolume 44pages10111012 (2019) | Download Citation

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Rasmussen K, White DA, Acri JB. NIDA's medication development priorities in response to the Opioid Crisis: ten most wanted. Neuropsychopharmacology, 2018. https://doi.org/10.1038/s41386-018-0292-5.

  2. 2.

    Mello NK, Negus SS. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology. 1996;14:375–24.

  3. 3.

    Negus SS, Banks ML. Medications development for opioid abuse. Cold Spring Harb Perspect Med. 2013;3:a012104.

  4. 4.

    Banks ML, Negus SS. Insights from preclinical choice models on treating drug addiction. Trends Pharmacol Sci. 2017;38:181–94.

  5. 5.

    Czoty PW, Stoops WW, Rush CR. Evaluation of the "pipeline" for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research. Pharmacol Rev. 2016;68:533–62.

  6. 6.

    Kowalczyk WJ, et al. Clonidine maintenance prolongs opioid abstinence and decouples stress from craving in daily life: a randomized controlled trial with ecological momentary assessment. Am J Psychiatry. 2015;172:760–7.

  7. 7.

    Mantsch JR, et al. Stress-induced reinstatement of drug seeking: 20 years of progress. Neuropsychopharmacology. 2016;41:335–56.

  8. 8.

    Ling W, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005;100:1090–100.

Download references

Acknowledgements

We appreciate comments from Dr. Kevin Freeman on an earlier version of the manuscript. We also appreciate the critical comments from the anonymous reviewers.

Author information

Affiliations

  1. Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298, USA

    • Matthew L. Banks
    • , E. Andrew Townsend
    •  & S. Stevens Negus

Authors

  1. Search for Matthew L. Banks in:

  2. Search for E. Andrew Townsend in:

  3. Search for S. Stevens Negus in:

Corresponding authors

Correspondence to Matthew L. Banks or S. Stevens Negus.

About this article

Publication history

Received

Revised

Accepted

Published

Issue Date

DOI

https://doi.org/10.1038/s41386-019-0336-5